Pre-Clinical Research

Found 7,359 articles

• 

  Biopharma Update on the Novel Coronavirus: September 25

  9/25/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 25, 2020.

• ImmunoPrecise and LiteVax SARS-CoV-2 Vaccine Begins Pre-Clinical Trials

  9/25/2020

   IMMUNOPRECISE ANTIBODIES LTD. ("IPA") (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, and LiteVax BV (Oss, the Netherlands), today announced that they have initiated pre-clinical vaccine trials against SARS-CoV-2.

• Clover Biopharmaceuticals Announces Positive Preclinical Data and Updates on Phase 1 Study for its Adjuvanted S-Trimer COVID-19 Vaccine Candidate

  9/25/2020

  Preclinical data show Clover’s protein-based adjuvanted COVID-19 vaccine candidate, S-Trimer, induces a strong neutralizing immune response in animalsand protects nonhuman primates from SARS-CoV-2 challenge

• Poxel Presents Imeglimin Phase 3 TIMES Results and PXL770 Preclinical Cardio-Renal Results at the 56th European Association for the Study of Diabetes Annual Meeting

  9/24/2020

  POXEL SA announced that it presented Imeglimin Phase 3 results for TIMES 2 and TIMES 3 and new preclinical results for PXL770 in a cardio-renal disease model at the 56th European Association for the Study of Diabetes Annual Meeting, which is being held virtually.

• 

  Biopharma Update on the Novel Coronavirus: September 23

  9/23/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 23, 2020.

• Mymetics Starts Preclinical Studies with Baylor College of Medicine for Virosome-based Covid-19 Vaccine

  9/23/2020

  Mymetics has started a Covid-19 vaccine development project based on Mymetics' virosome vaccine carrier platform, which will evaluate different rationally designed SARS-CoV-2 antigens for an effective and safe virosome-based Covid-19 vaccine.

• 

  Biopharma Update on the Novel Coronavirus: September 21

  9/21/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 21, 2020.

• Applied DNA Enters into Supply Agreement with ITW Pillar Technologies to Bring CertainT® Platform to Textiles Including Those Used in Personal Protective Equipment

  9/21/2020

  Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic acid-based therapeutic drug candidates, supply chain security, anti-counterfeiting and a

• 

  Biopharma Update on the Novel Coronavirus: September 18

  9/18/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.

• AstraZeneca acquires oral PCSK9 inhibitor programme from Dogma Therapeutics

  9/17/2020

  AstraZeneca has entered into an agreement with Dogma Therapeutics to acquire its preclinical oral PCSK9 inhibitor programme.

• ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020

  9/17/2020

  ESSA Pharma Inc. (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the presentation of data of ESSA's clinical candidate, EPI-7386, at the ESMO Virtual Congress 2020. 

• Passage Bio Announces Publication of Preclinical Gene Therapy Study Data from Frontotemporal Dementia Program

  9/17/2020

  Passage Bio, Inc. announced publication of data supporting development of its gene therapy PBFTO2 for patients with frontotemporal dementia caused by mutations in the granulin gene.

• Amunix to Present Preclinical Data on Protease-Activated HER2- and EGFR-Targeted T Cell Engagers at ESMO Virtual Congress 2020

  9/17/2020

  Data demonstrate potential of Amunix’s XPAT platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treating solid tumors

• 

  Biopharma Update on the Novel Coronavirus: September 16

  9/16/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 16, 2020.

• Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors

  9/16/2020

  Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today reported data demonstrating that its first-in-class KRASG12D(ON) inhibitors induced tumor regressions in a preclinical model of human pancreatic cancer carrying an oncogenic KRASG12D mutation.

• Wave Life Sciences to Highlight Preclinical ADAR Editing Data and Neurology Programs at TIDES and OTS Annual Meetings

  9/15/2020

  Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that it will highlight its ADAR (adenosine deaminases acting on RNA)-mediated RNA editing technology (“ADAR editing”) and its neurology programs in Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) at upcoming conferences,

• Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-in-Class Potential for ICON-2 in Treatment of Solid Tumors

  9/15/2020

  Exelixis, Inc. (Nasdaq: EXEL) and Iconic Therapeutics today announced new preclinical data that support the continued development of ICON-2, an ADC comprised of an anti-Tissue Factor (TF) antibody and Zymeworks’ proprietary linker-payload, for the treatment of diverse solid tumors

• 

  Biopharma Update on the Novel Coronavirus: September 14

  9/14/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.

• Talaris Therapeutics Announces Collaboration With Kentucky Organ Donor Affiliates to Advance Preclinical Study of Tolerance Induction to Organs From Deceased Donors

  9/14/2020

  Talaris Therapeutics, Inc. , a privately held biotechnology company developing transformative cell therapies that have the potential to induce durable immune tolerance across a range of indications, today announced a collaboration with Kentucky Organ Donor Affiliates (KODA). KODA is an independent, non-profit organ and tissue procurement organization that facilitates deceased donor transplants throughout K

• Global Preclinical Data Forum and European College of Neuropsychopharmacology Announce the Winner of the 2020 Best Negative Data Prize

  9/14/2020

  The Global Preclinical Data Forum (GPDF; https://www.preclinicaldataforum.org/), a jointly sponsored U.S. and European initiative, funded by Cohen Veterans Bioscience (CVB) and the European College of Neuropsychopharmacology (ECNP), announced today the winner of the 2020 "Best Negative Data Prize.